Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2
Open Access
- 1 September 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (17), 6382-6389
- https://doi.org/10.1158/1078-0432.ccr-05-0344
Abstract
Purpose: We determined the effects of suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, on hsp90 and its client proteins Her-2, AKT, and c-Raf, as well as evaluated the cytotoxic effects of cotreatment of SAHA with trastuzumab or docetaxel in human breast cancer BT-474 and SKBR-3 cells containing amplification of Her-2.Keywords
This publication has 49 references indexed in Scilit:
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3Blood, 2005
- Successful targeting of ErbB2 receptors—is PTEN the key?Cancer Cell, 2004
- Upstream and downstream of mTORGenes & Development, 2004
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004
- Survival signalling by Akt and eIF4E in oncogenesis and cancer therapyNature, 2004
- Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor DevelopmentThe Journal of Experimental Medicine, 2002
- Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondriaOncogene, 2001
- Molecular mechanisms underlying ErbB2/HER2 action in breast cancerOncogene, 2000